인쇄하기
취소

Janssen starts a new clinical trial as manufacturing issue is addressed

Published: 2017-06-13 10:01:48
Updated: 2017-06-13 10:01:48

Janssen, a multinational pharmaceutical company owning the license of JNJ-64565111, a Hanmi Pharm’s biologic for the treatment of diabetes and obesity, will start a new clinical trial at the end of this year as the ‘manufacturing delay’ issue was addressed.

Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) made a public announcement on the 9th “Janssen has recently finished the Phase 1 clinical tr...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.